Could a daily sip of carbon monoxide help control Parkinson's?
NCT ID NCT07005180
Summary
This study is testing the safety and drug levels of HBI-002, a daily oral liquid containing a low dose of carbon monoxide (CO), in people with Parkinson's disease. Over 14 days, 36 participants will take either the drug or a placebo. The main goal is to see if the treatment is safe and how the body processes it, as a first step toward seeing if it might help control Parkinson's symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.